On the stock market since 1981, it operates in the world of health and science. It has 77,406 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 22% a year over the last 4 years. Every year shown ended in profit.
The gap is $104B. In times of high interest rates, a gap like that can squeeze a company.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 33% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 20% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The stock trades 11% above the average analyst price target.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, NVO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NVO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.